ArticleFrontiers in oncology2026
Peripheral blood monocytes could be associated with brain metastasis and affect patient prognosis in breast cancer: a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to test the hypothesis that changes in peripheral blood monocyte-related ratios, particularly the lymphocyte-to-monocyte ratio (LMR), at the time of brain metastases (BM) diagnosis are associated with survival outcomes in patients with breast cancer. Methods: This study included 117 patients with breast cancer who developed BM from 2008 to 2023. We analyzed peripheral blood counts at primary diagnosis and at BM diagnosis to examine changes in monocyte count. The impact on survival was assessed using the monocyte-related ratios. Results: The absolute monocyte count (AMC) increased 2.11-fold at BM diagnosis compared with initial breast cancer diagnosis (p = 0.038). The high LMR group had a median survival of 20.0 months (95% CI 15.2-28.5) compared with 5.13 months (95% CI 3.9-7.5) in the low group (log-rank p < 0.001). Similarly, the high platelet-to-monocyte ratio (PMR) group had a median survival of 14.17 months (95% CI 7.0-18.7) versus 5.73 months (95% CI 3.6-9.9) in the low group (log-rank p = 0.028). Prognostic factors significantly associated with poorer survival included triple-negative breast cancer subtype, low LMR, and number of BMs, while age and extracranial metastasis exerted minimal impact. Conclusion: Changes in AMC and monocyte-related ratios at the time of BM diagnosis are associated with the development of BM and can impact survival outcomes in patients with breast cancer. These findings suggest that monocyte dynamics may serve as exploratory prognostic markers, which require validation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.